# Table of Contents

## BREAKING ADVANCES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2961</td>
<td>Highlights from Recent Cancer Literature</td>
</tr>
</tbody>
</table>

## REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2963</td>
<td>Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts</td>
</tr>
<tr>
<td>2969</td>
<td>Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing</td>
</tr>
</tbody>
</table>

## INTEGRATED SYSTEMS AND TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>2975</td>
<td>Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach</td>
</tr>
<tr>
<td>2987</td>
<td>Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy</td>
</tr>
<tr>
<td>2999</td>
<td>IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism</td>
</tr>
</tbody>
</table>

## MICROENVIRONMENT AND IMMUNOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>3020</td>
<td>Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4⁺ and CD8⁺ T Cell-Mediated Antitumor Immunity</td>
</tr>
<tr>
<td>3032</td>
<td>Oncogenic Transformation Can Orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure</td>
</tr>
<tr>
<td>3043</td>
<td>Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity</td>
</tr>
</tbody>
</table>

---

*August 1, 2015 • Volume 75 • Number 15*
3054  Tristetraprolin Limits Inflammatory Cytokine Production in Tumor-Associated Macrophages in an mRNA Decay–Independent Manner
Franz Kratochvill, Nina Grat, Joseph E. Qualil, Lee-Ann Van De Veldhe, Hongbo Chi, Pavel Kovarik, and Peter J. Murray
Précis: Manipulation of a p38 kinase-related signaling axis in macrophages appears to strongly affect the growth of solid tumors, suggesting a new strategy to reprogram inflammation in tumor microenvironments.

MOLECULAR AND CELLULAR PATHOBIOLOGY

3065  Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma
Liliana Soroceazu, Lisa Matlaf, Sabeena Khan, Armin Akhavan, Eric Singer, Vladimir Bezrookove, Stacy Decker, Saleena Ghanem, Piotr Hadaczek, Henrik Bengtsson, John Ohlfest, Maria Gloria Luciani-Torres, Lualhati Harkins, Arie Perry, Hong Guo, Patricia Soteropoulos, and Charles S. Cobbs
Précis: This study unveils a novel paradigm in viral oncogenesis, exposing the role of human cytomegalovirus in driving the growth of cancer stem cells in glioblastoma.

3077  EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1
Yung-Sheng Chang, Wei-Yu Chen, Juan Juan Yin, Heather Sheppard-Tillman, Jiaoti Huang, and Yen-Nien Liu
Précis: The findings of this study raise the interesting idea that miRNA expression might be directly targeted by nuclear growth factor receptor isoforms, with relevance for the coordinated progression of malignancy.

3087  KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78
Jin Muk Kang, Sujeon Park, Staci Jakyong Kim, Hyeoung Kim, Bona Lee, Junil Kim, Jinah Park, Shin Tae Kim, Han-Kwang Yang, Woo Ho Kim, and Seong-Jin Kim
Précis: These findings provide evidence of a novel mechanism of gastric carcinogenesis and also suggest a novel potential biomarker and therapeutic target for gastric cancer.

PREVENTION AND EPIDEMIOLOGY

3098  Interleukin-6 Stimulates Defective Angiogenesis
Ganga Gopinathan, Carla Milagre, Oliver M.T. Pearce, Louise E. Reynolds, Kairbaan Hodivala-Dille, David A. Leinster, Haihong Zhong, Robert E. Hollingsworth, Richard Thompson, James R. Whiteford, and Frances Balkwill
Précis: These findings have important implications for understanding abnormal angiogenic processes in cancer, as well as their connection to immune escape and the use of VEGF or IL6 targeting therapies in cancer patients.

3108  Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung
Précis: Genetic polymorphisms that affect DNA methylation of the DNA repair gene MGMT have strong clinical relevance in smokers, not only for cancer risk assessment but also for stratification of lung cancer patients for alkylation agent chemotherapy.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

3118  Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms
Shannon M. Gallagher-Colombo, Joann Miller, Keith A. Cengel, Mary E. Putt, Sergei A. Vinogradov, and Theresa M. Busch
Précis: These findings offer a strong impetus to incorporate the EGFR inhibitor erlotinib into clinical trials of photodynamic therapy, based on understanding drug mechanisms that rationalize its combination with other cytotoxic therapies.
3127  Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
José L. McFall-Figueroa, Christian J. Braun, Monica Stanciu, Zachary D. Nagel, Patrizia Mazzucato, Dewakar Sangaraju, Edvinas Cerniauskas, Kelly Barford, Amanda Vargas, Yinin Chen, Natalia Tretjakova, Jacqueline A. Lees, Michael T. Hemann, Forest M. White, and Leona D. Samson
Précis: Modest decreases in DNA mismatch repair factor MSH2 can dramatically alter chemosensitivity to a drug used commonly to treat aggressive cancers, with little effect on the mismatch repair itself, suggesting that subtle mismatch repair changes mediating drug resistance may be more prevalent than appreciated.

3139  Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Précis: Based on other advances in targeting FGF receptors in cancer, the novel mutations identified in this study in the extracellular domain of the FGFR2 receptor could offer therapeutic targets in a variety of solid tumors.

3147  Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Précis: These findings establish a clinically tractable method to safely widen the therapeutic window for chemotherapy in patients with liver cancer, along with a noninvasive method to identify candidate subjects, offering immediate translational impact for evaluation in human trials.

3155  CASC15-S Is a Tumor Suppressor IncRNA at the 6p22 Neuroblastoma Susceptibility Locus
Précis: This unbiased genetic association study identifies the involvement of a long noncoding RNA in initiating pediatric neuroblastoma, helping explain the low somatic mutation rates in protein coding genes observed in this lethal malignancy and suggesting new directions for therapeutic intervention.

3167  TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis
Anny Shai, David Dankort, Joseph Juan, Shon Green, and Martin McMahon
Précis: This study describes new mouse models for temporal dissociation of genetic events in lung carcinogenesis and establishes a core role for the p53 pathway in restricting lung cancer development.

3181  Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma
Tao Li, Junjie Xie, Xuan Shen, Dongfeng Cheng, Yuan Shi, Zhichong Wu, Xiaoxing Deng, Hao Chen, Baiyong Shen, Chenghong Peng, Hongwei Li, Qian Zhan, and Zhecheng Zhu
Précis: These findings illuminate the oncogenic function of a noncoding RNA that acts by opposing tumor-suppressive effects of miR-150, suggesting utility as a prognostic biomarker or target for clinical management of HCC.
ABOUT THE COVER

The immunofluorescence image is of an aortic ring treated with IL6 stained for vessels (green), pericytes (red), and cell nuclei (blue). Here, it is shown that IL6 stimulates angiogenesis with defective pericyte coverage. Treatment of peritoneal xenografts of ovarian cancer with an anti-IL6 antibody restored pericyte coverage of the tumor blood vessels. The authors’ findings have implications for the use of cancer therapies that target IL6 and for understanding abnormal angiogenesis in cancers, chronic inflammatory disease, and stroke. For details, see article by Gopinathan and colleagues on page 3098.